Byung Moo Yoo

Byung Moo Yoo

Auto-generated profile, based on publicly available information

Byung Moo Yoo

Department of Gastroenterology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Gut and Liver
Verified
Journal Article
Open access
PDF file
HCHyo Jung Cho
Hyo Jung Cho
SHSunhyuk Hwang
Sunhyuk Hwang
JPJong Ik Park
Jong Ik Park
MYMin Jae Yang
Min Jae Yang
JHJae Chul Hwang
Jae Chul Hwang
SKSoon Sun Kim
Soon Sun Kim
Hyo Jung Cho, Sunhyuk Hwang , Jong Ik Park, Min Jae Yang, Jae Chul Hwang, Byung Moo Yoo, Kee Myung Lee, Sung Jae Shin, Kwang Jae Lee, Jin Hong Kim, Jae Youn Cheong, Sung Won Cho, and Soon Sun Kim. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl18382

19 February 2018 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
EYEun Soo Yoo
Eun Soo Yoo
BYByung Moo Yoo
Byung Moo Yoo
JKJin Hong Kim
Jin Hong Kim
JHJae Chul Hwang
Jae Chul Hwang
MYMin Jae Yang
Min Jae Yang
CNChoong-kyun Noh
Choong-kyun Noh
Objectives: Recurrence of primary common bile duct (CBD) stone commonly occurs after complete removal of CBD stones in patients with cholecystectomy. This study aimed to investigate potential risk factors for the recurrence of primary CBD stones after endoscopic treatment. Materials and methods: Between January 2005 and December 2015, the endoscopic retrograde cholangiopancreatography (ERCP) database of our medical center was retrospectively reviewed; information regarding eligible patients who had recurrent CBD stones with a history of previous cholecystectomy was collected. The characteristics of the patients, CBD stone, CBD and ERCP-related factors were analyzed. Results: The recurrence rate of CBD stone was 18.5% (115/622) after endoscopic treatment in patients with cholecystectomy. In univariate analysis, the number of CBD stones (≥2), CBD stone diameter (≥10 mm), stone composition, stone consistency, CBD diameter (≥15 mm), bile duct dilatation pattern, sharp bile duct angulation (12 mm) dilatation, endoscopic mechanical lithotripsy, endoscopic sphincterotomy, and endoscopic papillary balloon dilatation alone method were significant between the non-recurrence and recurrence groups. However, in multivariate analysis (based on the binary logistic regression method), the number of CBD stones (≥2) (adjusted odds ratio [AOR] 3.232; 95% confidence interval [CI] 1.344–7.773; p = .009), cholesterol stone (AOR 2.824; 95% CI 1.175–6.786; p =.02) and sharp bile duct angulation (<145°) (AOR 2.462; 95% CI 1.062–5.711; p = .036) were independent risk factors of CBD stone recurrence after cholecystectomy. Conclusions: CBD stone number (≥2), cholesterol stone and sharp bile duct angulation (<145°) are associated with recurrent common bile duct stones after cholecystectomy.

29 September 2015 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MYMin Jae Yang
Min Jae Yang
HYHyunee Yim
Hyunee Yim
JHJae Chul Hwang
Jae Chul Hwang
DLDakeun Lee
Dakeun Lee
YKYoung Bae Kim
Young Bae Kim
JKJin Kim
Jin Kim
Biopsy needles have recently been developed to obtain both cytological and histological specimens during endoscopic ultrasound (EUS). We conducted this study to compare 22-gauge (G) fine needle aspiration (FNA) needles, which have been the most frequently used, and new 25G fine needle biopsy (FNB) needles for EUS-guided sampling of solid pancreatic masses. We conducted a retrospective cohort study of all EUS-guided sampling performed between June 2010 and October 2013. During the study period, 76 patients with pancreatic masses underwent EUS-guided sampling with a 22G FNA needle (n = 38) or a 25G FNB needle (n = 38) for diagnosis. An on-site cytopathologist was not present during the procedure. Technical success, the number of needle passes, cytological diagnostic accuracy, cytological sample quality (conventional smear and liquid-based preparation), histological diagnostic accuracy, and complications were reviewed and compared. There were no significant differences in technical success (100 % for both), the mean number of needle passes (5.05 vs. 5.55, P = 0.132), or complications (0 % for both) between the 22G FNA group and the 25G FNB group. The 22G FNA and 25G FNB groups exhibited comparable outcomes with respect to cytological diagnostic accuracy (97.4 % vs. 89.5 %, P = 0.358) and histological diagnostic accuracy (34.2 % vs. 52.6 %, P = 0.105). In the cytological sample quality analysis, the 25G FNB group exhibited higher scores for the amount of diagnostic cellular material present (22G FNA: 0.92 vs. 25G FNB: 1.32, P = 0.030) and the retention of appropriate architecture (22G FNA: 0.97 vs. 25G FNB: 1.42, P = 0.010) in the liquid-based preparation. The 25G FNB group showed a better histological diagnostic yield for specific tumor discrimination compared with the 22G FNA group (60 % vs. 32.4 %, P = 0.018). Use of the 25G FNB needle was technically feasible, safe, efficient, and comparable to use of the standard 22G FNA needle in patients with solid pancreatic masses in the absence of an on-site cytopathologist. The cytological sample quality in the liquid-based preparation and the histological diagnostic yield for specific tumor discrimination of EUS-guided sampling using a 25G FNB needle were significantly higher than those using a 22G FNA needle.

28 October 2015 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MYMin Jae Yang
Min Jae Yang
JHJae Chul Hwang
Jae Chul Hwang
BYByung Moo Yoo
Byung Moo Yoo
JKJin Kim
Jin Kim
HRHyoung-Kyu Ryu
Hyoung-Kyu Ryu
MKMin Kyeong Kim
Min Kyeong Kim
In cases of difficult bile duct cannulation, the use of wire-guided cannulation over a pancreatic stent (WGC-PS) or the double guidewire technique (DGT) may facilitate biliary cannulation. The aim of this study was to compare the outcomes of WGC-PS and DGT in patients with difficult biliary cannulation. We conducted a retrospective cohort study of all endoscopic retrograde cholangiopancreatographies (ERCPs) performed between July 2009 and November 2014 at a single tertiary referral center. WGC-PS or DGT was performed in patients for whom biliary cannulation was difficult and guidewire insertion into the pancreatic duct (PD) was inadvertently achieved while attempting the standard WGC technique. In those cases, we used the WGC-PS technique from July 2009 to January 2012 (WGC-PS group), and the DGT technique from February 2012 to November 2014 (DGT group). In the DGT group, WGC-PS was sequentially performed if successful biliary cannulation was not achieved during the DGT attempt. Consecutive patients who underwent DGT and/or WGC-PS with the aim of selective biliary cannulation were enrolled. The primary outcome parameter was the rate of initial successful biliary cannulation. During the study period 3270 ERCPs were performed and a total of 177 patients were enrolled. The rate of initial successful cannulation was 66.7 % (60/90) in the WGC-PS group and 70.1 % (61/87) in the DGT group (P = 0.632). In 26 cases of failed DGT, WGC-PS was sequentially performed in the DGT group, and cannulation was successful in 14 of these patients. The rate of successful cannulation without the needle-knife precut technique was significantly higher in the DGT group compared with the WGC-PS group (75/87, 86.2 % vs. 60/90, 66.7 %, P = 0.003). The incidence of post-ERCP pancreatitis was 3.3 % (3/90) in the WGC-PS group and 10.3 % (9/87) in the DGT group (P = 0.077). In patients for whom biliary cannulation was difficult and PD access was inadvertently achieved while attempting the standard WGC technique, both WGC-PS and DGT were equally effective. Furthermore, the stepwise approach using DGT followed by WGC-PS as needed facilitated successful biliary cannulation and reduced the need for the needle-knife precut technique.

1 January 2017 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YLYeon Kyung Lee
Yeon Kyung Lee
MYMin Jae Yang
Min Jae Yang
SKSoon Sun Kim
Soon Sun Kim
CNChoong-kyun Noh
Choong-kyun Noh
HCHyo Jung Cho
Hyo Jung Cho
JKJin Kim
Jin Kim
Lee YK, et al. J Korean Med Sci. 2017 Nov;32(11):1814-1819. https://doi.org/10.3346/jkms.2017.32.11.1814

Verified
Journal Article
Open access
PDF file
SCSungYoon Cho
SungYoon Cho
SJSeong Mun Jeong
Seong Mun Jeong
YJYoung Joo Jeon
Young Joo Jeon
SYSun Ja Yang
Sun Ja Yang
JHJu Eun Hwang
Ju Eun Hwang
HKHyun Soo Kim
Hyun Soo Kim
Dendritic cells (DC) are powerful cells that play critical roles in anti-tumor immunity, and their use in cancer immunotherapy unlocks hidden capabilities as an effective therapeutic. In order to maximize the full potential of DC, we developed a DC vaccine named CellgramDC-WT1 (CDW). CDW was pulsed with WT1, an antigen commonly expressed in solid tumors, and induced with zoledronate to aid DC maturation. Although our previous study focused on using Rg3 as an inducer of DC maturation, problems with quality control and access led us to choose zoledronate as a better alternative. Furthermore, CDW secreted IL-12 and IFN-γ, which induced the differentiation of naïve T cells to active CD8+ T cells and elicited cytotoxic T lymphocyte (CTL) response against cancer cells with WT1 antigens. By confirming the identity and function of CDW, we believe CDW is an improved DC vaccine and holds promising potential in the field of cancer immunotherapy.